Exploring new treatment targets for head and neck cancers
Official title: A Cohort Study to Identify Newer Therapeutic Targets in Head and Neck Cancers
Run by Banaras Hindu University · NCT05382585 · Data updated 2026-11-12
This study is trying to find out how certain genetic changes and HPV relate to head and neck cancers in patients with oral squamous cell carcinoma to help improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Banaras Hindu University Academic / other |
| Locations | 1 site (Varanasi, Uttar Pradesh) |
| Status | Recruiting |
| Started | April 1, 2017 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 13, 2024 |
| Trial ID | NCT05382585 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults with histologically confirmed primary head and neck cancers.
✕Probably not a fit
Patients under 18 years of age, pregnant or lactating women, and those with multiple cancers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with squamous cell carcinoma of the oral cavity to investigate the role of specific genetic mutations in tumorigenesis. It involves comprehensive patient evaluations, including physical examinations, biopsies, and imaging studies to assess tumor characteristics. The study utilizes next-generation sequencing to analyze genetic alterations in tumor samples, aiming to identify predictive biomarkers that could guide treatment decisions. Additionally, HPV typing will be performed to understand its association with head and neck cancers.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostication and personalized treatment strategies for patients with head and neck cancers.
How similar studies have gone: Other studies utilizing next-generation sequencing for cancer biomarker identification have shown promising results, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven cases of primary head and neck cancers. Exclusion Criteria: * Patients under 18 years of age * Pregnant and lactating women * Multiple cancers or patients with cancer of other sites.
Where it's running
-
Banaras Hindu University
Varanasi, Uttar Pradesh, India Recruiting
Study contacts
- Principal investigator: Manoj Pandey, MS, PhD — Professor
- Study coordinator: Manoj Pandey, MS, PhD
- Email: manojpandey66@gmail.com
- Phone: 9336363640
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proton Re-irradiation for Recurrent or Second Primary Head and Neck Cancer
This study tests proton radiotherapy to see if it can control head and neck cancer that has come back or appeared again in the same area, while trying to limit side effects.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
Intratumoral fluorescent nivolumab before surgery in head and neck cancer
This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.
-
BupiZenge vs Lidocaine for mouth pain from oral mucositis in head and neck cancer
A phase 3 trial tests whether the BupiZenge lozenge provides better pain relief than lidocaine for mouth sores caused by radiation in head and neck cancer patients.
-
Proton Re-irradiation for Head and Neck Cancer Recurrence
This study tests whether proton therapy as a second round of radiation is safe and helpful for adults with head and neck cancer that has come back after prior treatment.
-
Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer
This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.